Brilaroxazine

Brilaroxazine is an atypical antipsychotic that is used in the treatment of schizophrenia. It was developed by Reviva Pharmaceuticals and was approved by the FDA in the United States in 2020.

History

Brilaroxazine was first developed by Reviva Pharmaceuticals, a company based in the United States. The drug was approved by the FDA in 2020 for the treatment of schizophrenia.

Pharmacology

Brilaroxazine is an atypical antipsychotic, which means it works differently than traditional antipsychotics. It is believed to work by blocking certain receptors in the brain, including dopamine and serotonin receptors. This can help to reduce the symptoms of schizophrenia.

Uses

Brilaroxazine is used to treat schizophrenia, a mental disorder that can cause hallucinations, delusions, and other cognitive difficulties. It can be used in adults as a standalone treatment or in combination with other medications.

Side Effects

Like all medications, brilaroxazine can cause side effects. These can include drowsiness, dizziness, and weight gain. In rare cases, it can cause serious side effects like tardive dyskinesia, a condition that causes uncontrollable movements.

See Also

• Atypical antipsychotic
• Schizophrenia
• Reviva Pharmaceuticals
• Food and Drug Administration

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

References

<references />

External Links

• Reviva Pharmaceuticals
• Food and Drug Administration

Further Reading

• "Brilaroxazine: A New Atypical Antipsychotic Drug for the Treatment of Schizophrenia"